Chronic myelogenous leukemia (cml)
Drug research and approvals for chronic myelogenous leukemia (cml): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 95 studies of chronic myelogenous leukemia (cml) are recruiting on ClinicalTrials.gov, Health Canada has authorized 9 drug trials for it since 2013, FDA has 20 approved and 16 open orphan designations naming it, and the EU has 10 authorised medicines for it.
- Recruiting worldwide: 95
- Trials authorized in Canada: 9
- FDA orphan approvals: 20
- EU medicines: 10
Recruiting Now
Newest start dates first, of 95 recruiting on ClinicalTrials.gov ↗- Efficacy of Asciminib in Chronic Phase CML Patients With T315I MutationsNCT07789574 · Phase 2 · Thomas Ernst, Prof. Dr. med. · starts Nov 1, 2026
- Allogeneic iNKT Cell Therapy (agenT-797) After SCTNCT07758218 · Phase 1 · University of Wisconsin, Madison · starts Nov 1, 2026
- Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients…NCT06904066 · Phase 1 · National Cancer Institute (NCI) · starts Oct 28, 2026
- Prophylactic DLI-X for Leukemia Relapse After HCTNCT07254793 · Phase 1 · University of Arizona · starts Oct 26, 2026
- A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in…NCT07020533 · Phase 1 · City of Hope Medical Center · starts Sep 9, 2026
- TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCTNCT07302776 · Phase 1 · Stanford University · starts Jul 21, 2026
- Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With…NCT07269470 · Phase 2 · M.D. Anderson Cancer Center · starts Jul 13, 2026
- Therapeutic RSK1 Targeting in Myeloid MalignanciesNCT07379125 · Phase 1 · Washington University School of Medicine · starts May 20, 2026
- Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPNCT07354074 · Phase 2 · Novartis Pharmaceuticals · starts Apr 28, 2026
- A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive…NCT07549516 · Not reported · Novartis Pharmaceuticals · starts Apr 17, 2026
Trials Authorized in Canada
Newest first; search them all in Canada trials| Feb 27, 2026 | A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of asciminib in pediatric participants newly diagnosed or previously…ASCIMINIB (ABL001) | Novartis Pharmaceuticals Corporation | Ongoing |
| Feb 12, 2026 | Asciminib, with or without dasatinib combination, as a 2nd-line therapy to advance the treatment for chronic myelogenous leukemia in chronic phase (asc2advance)ASCIMINIB | UNIVERSITY HEALTH NETWORK | Ongoing |
| May 10, 2022 | A phase 3, multicenter, randomized, open-label, trial evaluating the efficacy and safety of asciminib (abl001) used in consolidation with imatinib vs. imatinib…ASCIMINIB (ABL001) | JEWISH GENERAL HOSPITAL | Closed |
| Oct 27, 2021 | A phase 3b, multi-center, open-label, treatment optimization study of oral asciminib in patients with chronic myelogenous leukemia in chronic phase (cml-cp)…ASCIMINIB (ABL001) | Novartis Pharmaceuticals Corporation | Closed |
| Sep 27, 2021 | A phase III, multi-center, open-label, randomized study of oral asciminib versus investigator selected tki in patients with newly diagnosed philadelphia…ASCIMINIB (ABL001) | Novartis Pharmaceuticals Corporation | Ongoing |
| Sep 14, 2021 | An open label, multi-center asciminib roll-over study to assess long-term safety in patients who have completed a novartis sponsored asciminib study and are…ASCIMINIB (ABL001) / IMATINIB (STI571) | Novartis Pharmaceuticals Corporation | Ongoing |
| Aug 27, 2021 | Phase 3 randomized, controlled study of blinatumomab alternating with low-intensity chemotherapy versus standard of care for older adults with newly diagnosed…BLINCYTO | Amgen | Ongoing |
| Sep 14, 2018 | A phase 2, multi-center, open-label, randomized study of oral asciminib added to imatinib versus continued imatinib versus switch to nilotinib in patients with…ASCIMINIB (ABL001)/ IMATINIB/ NILOTINIB | Novartis Pharmaceuticals Corporation | Closed |
| Jun 15, 2017 | A phase 3, multi-center,open-label, randomized study of oral abl001 versus bosutinib in patients with chronic myelogenous leukemia in chronic pahse (cml-cp),…ASCIMINIB (ABL-001)/ BOSUTINIB | Novartis Pharmaceuticals Corporation | Closed |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 36| May 29, 2026 | Cavhanzatreatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase; and… | Cycle Pharmaceuticals Ltd | Approved |
| Aug 1, 2025 | Phyragotreatment of pediatric patients 1 year of age and older with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in… | Handa Therapeutics, LLC | Approved |
| Nov 7, 2024 | Danzitentreatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase; and… | Azurity Pharmaceuticals, Inc. | Approved |
| Oct 29, 2024 | Scemblixtreatment of adult patients with previously treated Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase… | Novartis Pharmaceuticals Corporation | Approved |
| Oct 29, 2024 | Scemblixtreatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) | Novartis Pharmaceuticals Corporation | Approved |
| Dec 5, 2023 | Phyragotreatment of adult patients with: newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase;… | Handa Therapeutics, LLC | Approved |
| Sep 26, 2023 | Bosuliftreatment of pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome positive chronic myelogenous… | PF PRISM C.V. | Approved |
| Oct 29, 2021 | ScemblixTreatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously… | Novartis Pharmaceuticals Corporation | Approved |
| Oct 29, 2021 | ScemblixTreatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) with the T315I… | Novartis Pharmaceuticals Corporation | Approved |
| Sep 23, 2021 | TasignaTreatment of pediatric patients greater than or equal to 1 year of age with chronic phase and accelerated phase Philadelphia chromosome… | Novartis Pharmaceuticals Corporation | Approved |
| Mar 22, 2018 | TasignaTASIGNA® (nilotinib) is indicated for the treatment of pediatric patients greater than or equal to 1 year of age with newly diagnosed… | Novartis Pharmaceuticals Corporation | Approved |
| Dec 19, 2017 | BosulifBOSULIF is indicated for the treatment of adult patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic… | PF PRISM C.V. | Approved |
| Nov 9, 2017 | SprycelTreatment of pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase | Bristol-Myers Squibb Company | Approved |
| Dec 14, 2012 | IclusigTreatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or… | Takeda Pharmaceuticals U.S.A., Inc. | Approved |
| Oct 26, 2012 | SynriboTreatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or… | IVAX International GmbH | Approved |
Medicines Authorised in the EU
Newest first| Aug 22, 2024 | Nilotinib Accordnilotinib · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Jul 26, 2024 | Dasatinib Accord Healthcaredasatinib · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Aug 25, 2022 | Scemblixasciminib · orphan | Novartis Europharm Limited | EMA ↗ |
| Jul 1, 2013 | Iclusigponatinib | Incyte Biosciences Distribution B.V. | EMA ↗ |
| Jun 30, 2013 | Imatinib Accordimatinib · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Mar 27, 2013 | Bosulifbosutinib | Pfizer Europe MA EEIG | EMA ↗ |
| Jan 7, 2013 | Imatinib Tevaimatinib · generic | Teva B.V. | EMA ↗ |
| Nov 19, 2007 | Tasignanilotinib | Novartis Europharm Limited | EMA ↗ |
| Nov 20, 2006 | Spryceldasatinib (anhydrous) | Bristol-Myers Squibb Pharma EEIG | EMA ↗ |
| Nov 7, 2001 | Glivecimatinib | Novartis Europharm Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA